Review
Oncology
Maria Teresa Climent, Anna Serra, Maria Llueca, Antoni Llueca
Summary: Ovarian cancer has a high mortality rate due to advanced diagnosis and high recurrence rate. Systemic chemotherapy is the standard treatment for recurrent ovarian cancer, but secondary cytoreductive surgery may also be effective. This study analyzed multiple randomized controlled trials and found significant improvements in overall survival and disease-free survival for patients who underwent complete secondary cytoreductive surgery.
Article
Oncology
Se Ik Kim, Ji Hyun Kim, Sanghee Lee, Hyunsoon Cho, Willemien J. van Driel, Gabe S. Sonke, Robert E. Bristow, Sang-Yoon Park, Christina Fotopoulou, Myong Cheol Lim
Summary: This study systematically evaluated the value of hyperthermic intraperitoneal chemotherapy (HIPEC) in cytoreductive surgery (CRS) for epithelial ovarian cancer (EOC). The results showed that HIPEC improved progression-free survival (PFS) and overall survival (OS) in the recent chemotherapy exposure group, but had no significant effect in the non-recent chemotherapy exposure group.
GYNECOLOGIC ONCOLOGY
(2022)
Article
Oncology
Min-Hyun Baek, Eun Young Park, Hyeong In Ha, Sang-Yoon Park, Myong Cheol Lim, Christina Fotopoulou, Robert E. Bristow
Summary: This study focused on evaluating the survival impact of secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer. The findings indicated that complete cytoreductions were associated with better survival outcomes and that maximal tumor resection significantly increased overall survival in this patient population.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Arpita Suri, Vanamail Perumal, Prajwal Ammalli, Varsha Suryan, Sanjiv Kumar Bansal
Summary: The study compared the diagnostic accuracy of ROMA, HE-4, and CA125 in early diagnosis and screening of epithelial ovarian cancer. ROMA was found to be the best marker for differentiating EOC from benign ovarian masses in postmenopausal women, while HE4 showed promise as a diagnostic predictor in premenopausal women. Further research is needed to explore the full potential of HE4 in premenopausal women.
SCIENTIFIC REPORTS
(2021)
Review
Nutrition & Dietetics
Hui Luo, Hong Ge
Summary: This meta-analysis suggests that drinking hot tea is significantly associated with an increased risk of esophageal squamous cell carcinoma (ESCC), but not with esophageal adenocarcinoma (EAC).
FRONTIERS IN NUTRITION
(2022)
Review
Cell Biology
Yang Shao, Jing Kong, Hanzi Xu, Xiaoli Wu, YuePeng Cao, Weijian Li, Jing Han, Dake Li, Kaipeng Xie, Jiangping Wu
Summary: Our study included 476 ovarian cancer patients and 385 controls from eight eligible studies. The association between OPCML methylation and ovarian cancer risk was significant in various subgroups, and the findings were further validated by analyzing GEO and TCGA datasets. OPCML methylation was found to be related to advanced cancer stage and poorly differentiated grade, and specific CpG sites in the OPCML promoter region were significantly higher in cancer tissues compared to normal tissues. However, no associations were observed with clinicopathological parameters and overall survival based on TCGA ovarian cancer data. Overall, our findings support the link between OPCML methylation and increased ovarian cancer risk.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Review
Endocrinology & Metabolism
Ziyu Chen, Zesi Liu, Hongxia Yang, Chaosheng Liu, Fandou Kong
Summary: This study conducted a systematic review and meta-analysis to examine the association between metabolic syndrome (MetS) and ovarian cancer risk. The results showed no significant correlation between MetS and ovarian cancer risk. Only the unadjusted stratification of smoking and hysterectomy risk demonstrated a relationship between MetS and ovarian cancer risk.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Review
Oncology
Jiao Guo, Haoshen Feng, Xi Gu
Summary: This systematic review and meta-analysis examined the association between benign ovarian tumors and ovarian cancer risk. The results showed that benign ovarian tumors were associated with an increased risk of ovarian cancer, but there was high heterogeneity among studies. The risk varied depending on the histological type of the tumor.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Xiaxia Man, Baogang Wang, Yuying Tan, Xiaolin Yang, Songling Zhang
Summary: The meta-analysis showed that there was no statistically significant association between aspirin use and mortality in women with ovarian cancer. The results were consistent for ovarian cancer-specific mortality and all-cause mortality. Stratified analyses indicated that aspirin use did not have a significant association with mortality risk in ovarian cancer patients, regardless of various factors. Funnel plots suggested a potential risk of publication bias, but further trim-and-fill analysis showed similar results.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Peng Chen, Chi-Yuan Zhang
Summary: This study evaluated whether endometriosis had influence on the survival outcomes of ovarian cancer (OC) through a meta-analysis. The results showed that endometriosis-associated ovarian cancer (EAOC) patients tended to have better overall survival (OS) and progression-free survival (PFS) than non-EAOC patients.
FRONTIERS IN ONCOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Nanna Lond Skov Frisk, Anja Elaine Sorensen, Ole Birger Vesterager Pedersen, Louise Torp Dalgaard
Summary: In this study, a systematic review and meta-analysis were conducted to evaluate the global research potential of different circulating miRNAs as an early diagnostic biomarker for ovarian cancer (OC). The primary search resulted in 1887 articles, and 44 relevant studies were identified. Nine miRNAs were found to be dysregulated in OC patients compared to controls, with miR-21, -125, -141, -145, -205, -328, -200a, -200b, and -200c being upregulated. Future studies of circulating miRNAs in relation to OC should consider factors such as sample size, consensus guidelines, and coverage of previously reported miRNAs.
Review
Health Care Sciences & Services
Alessia Romito, Sonia Bove, Ilaria Romito, Drieda Zace, Ivano Raimondo, Simona Maria Fragomeni, Pierluigi Maria Rinaldi, Domenico Pagliara, Antonella Lai, Fabio Marazzi, Claudia Marchetti, Ida Paris, Gianluca Franceschini, Riccardo Masetti, Giovanni Scambia, Alessandra Fabi, Giorgia Garganese
Summary: Breast cancer is the most common malignancy in the female population worldwide, with an increasing diagnosis rate in young women and a growing desire for fertility preservation. AMH is considered a good surrogate for ovarian reserve, and studies show a significant decline in AMH levels after chemotherapy, which can guide fertility preservation choices for young women before treatment.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Review
Oncology
Massimiliano Fornasiero, Georgios Geropoulos, Konstantinos S. Kechagias, Kyriakos Psarras, Konstantinos Katsikas Triantafyllidis, Panagiotis Giannos, Georgios Koimtzis, Nikoletta A. Petrou, James Lucocq, Christos Kontovounisios, Dimitrios Giannis
Summary: Bowel resection is a necessary procedure for ovarian cancer treatment, but it can lead to anastomotic leakage, a common and serious complication. This meta-analysis identified multiple bowel resections as the only significant risk factor for anastomotic leaks. Further research is needed to identify additional risk factors and develop strategies to minimize the risk of anastomotic leaks in this population.
Review
Oncology
Benshuo Cai, Kang Li, Gang Li
Summary: Obesity is associated with an increased risk of postoperative complications, especially wound complications and infection after primary ovarian cancer surgery. However, obesity may not affect the rates of optimal debulking and 30-day mortality in patients undergoing ovarian cancer surgery. Additionally, an advanced minimally invasive robotic approach seems to be feasible for improving surgical outcomes in obese patients with ovarian cancer.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Lauren M. Hurwitz, Mary K. Townsend, Susan J. Jordan, Alpa V. Patel, Lauren R. Teras, James V. Lacey, Jennifer A. Doherty, Holly R. Harris, Marc T. Goodman, Yurii B. Shvetsov, Francesmary Modugno, Kirsten B. Moysich, Kim Robien, Anna Prizment, Joellen M. Schildkraut, Andrew Berchuck, Renee T. Fortner, Andrew T. Chan, Nicolas Wentzensen, Patricia Hartge, Dale P. Sandler, Katie M. O'Brien, Hoda Anton-Culver, Argyrios Ziogas, Usha Menon, Susan J. Ramus, Celeste Leigh Pearce, Anna H. Wu, Emily White, Ulrike Peters, Penelope M. Webb, Shelley S. Tworoger, Britton Trabert
Summary: The study found that frequent aspirin use is associated with lower ovarian cancer risk, regardless of other ovarian cancer risk factors in subgroups.
JOURNAL OF CLINICAL ONCOLOGY
(2022)